Zai Lab/$ZLAB
1D1W1MYTD1Y5YMAX
Capital at risk
About Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
- Ticker
- $ZLAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,784
- Headquarters
- Pudong, China
- Website
- www.zailaboratory.com
Zai Lab Metrics
BasicAdvanced
$2.9B
-
-$1.70
0.78
-
Price and volume
Market cap
$2.9B
Beta
0.78
52-week high
$34.72
52-week low
$15.96
Average daily volume
1.2M
Financial strength
Current ratio
2.133
Quick ratio
1.611
Long term debt to equity
0.019
Total debt to equity
0.419
Interest coverage (TTM)
-44.13%
Profitability
EBITDA (TTM)
-248.168
Gross margin (TTM)
3.78%
Net profit margin (TTM)
-41.86%
Operating margin (TTM)
-58.74%
Effective tax rate (TTM)
1.32%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-14.75%
Return on equity (TTM)
-26.91%
Valuation
Price to revenue (TTM)
6.335
Price to book
4.75
Price to tangible book (TTM)
5.56
Price to free cash flow (TTM)
-17.525
Free cash flow yield (TTM)
-5.71%
Free cash flow per share (TTM)
-1.466
Growth
Revenue change (TTM)
5.10%
Earnings per share change (TTM)
-16.46%
3-year revenue growth (CAGR)
21.32%
3-year earnings per share growth (CAGR)
-25.38%
What the Analysts think about Zai Lab
Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.
Analyst projections of the future price of Zai Lab stock.
Zai Lab Financial Performance
Revenues and expenses
Zai Lab Earnings Performance
Company profitability
Upcoming events
No upcoming events
Zai Lab News
AllArticlesVideos
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Business Wire1 month ago
Zai Lab Q2 Earnings Call Highlights
MarketBeat1 month ago
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Business Wire1 month ago
Funds containing Zai Lab
AllUSDGBP
Fund name | Fund size | $ZLAB weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.